系统评价使用与国家新生儿罕见病筛查政策推荐之间的关联:系统评价与Meta分析
该研究通过检索26个国家筛查机构网站,纳入93份报告、覆盖14个国家104种疾病共276条推荐,分析是否使用系统评价方法与推荐筛查之间的关联。结果显示仅22%推荐包含系统评价,使用系统评价与推荐筛查概率降低相关(OR 0.17,95%CI 0.07-0.43),且许多推荐未评估检测准确性、早期发现获益和过度诊断证据。
要点
- 仅22%的新生儿筛查推荐包含系统评价。
- 使用系统评价与推荐筛查概率降低相关(OR 0.17)。
- 多数推荐未评估检测准确性、早期发现获益或过度诊断证据。
核心结论
- 使用系统评价方法与推荐筛查概率降低相关。
- 许多国家新生儿罕见病筛查政策审查未评估筛查关键获益与危害证据。
研究设计与样本
- 系统评价与Meta分析,检索26个国家筛查机构网站。
- 纳入93份报告,覆盖14个国家104种疾病,共276条推荐。
主要发现
- 159条(58%)推荐支持筛查,98条(36%)不支持,19条(7%)未明确推荐。
- 仅60条(22%)推荐包含系统评价。
- 使用系统评价组推荐筛查比例38%(23/60),未使用组63%(136/216),OR 0.17(95%CI 0.07-0.43)。
- 未考虑检测准确性证据的推荐115条(42%),未考虑早期发现获益83条(30%),未考虑过度诊断211条(76%)。
临床怎么用
- 制定新生儿筛查政策时应采用系统评价方法评估检测准确性、早期发现获益和过度诊断危害。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To understand whether international differences in recommendations of whether to screen for rare diseases using the newborn blood spot test might in part be explained by use of systematic review methods. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Website searches of 26 national screening organisations. ELIGIBILITY CRITERIA FOR STUDY SELECTION: Journal articles, papers, legal documents, presentations, conference abstracts, or reports relating to a national recommendation on whether to screen for any condition using the newborn blood spot test, with no restrictions on date or language. DATA EXTRACTION: Two reviewers independently assessed whether the recommendation for or against screening included systematic reviews, and data on test accuracy, benefits of early detection, and potential harms of overdiagnosis. ANALYSIS: The odds of recommending screening according to the use of systematic review methods was estimated across conditions using meta-analysis. RESULTS: 93 reports were included that assessed 104 conditions across 14 countries, totalling 276 recommendations (units of analysis). Screening was favoured in 159 (58%) recommendations, not favoured in 98 (36%), and not recommended either way in 19 (7%). Only 60 (22%) of the recommendations included a systematic review. Use of a systematic review was associated with a reduced probability of screening being recommended (23/60 (38%) v 136/216 (63%), odds ratio 0.17, 95% confidence interval 0.07 to 0.43). Of the recommendations, evidence for test accuracy, benefits of early detection, and overdiagnosis was not considered in 115 (42%), 83 (30%), and 211 (76%), respectively. CONCLUSIONS: Using systematic review methods is associated with a reduced probability of screening being recommended. Many national policy reviews of screening for rare conditions using the newborn blood spot test do not assess the evidence on the key benefits and harms of screening.
引用
- Taylor-Phillips S, Stinton C, Ferrante di Ruffano L, et al. Association between use of systematic reviews and national policy recommendations on screening newborn babies for rare diseases: systematic review and meta-analysis. BMJ. 2018. PMID: 29743278. doi:10.1136/bmj.k1612
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。